MedPacto, Inc. (235980.KQ)
KRW 4585.0
(-1.4%)
KRW 4585.0
(-1.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.32 Billion KRW | 1.2% |
| 2022 | -35.75 Billion KRW | -109.82% |
| 2021 | -17.03 Billion KRW | 32.79% |
| 2020 | -25.35 Billion KRW | -87.58% |
| 2019 | -13.51 Billion KRW | 64.03% |
| 2018 | -37.57 Billion KRW | -983.45% |
| 2017 | -3.46 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.68 Billion KRW | 49.54% |
| 2024 Q1 | -9.27 Billion KRW | -22.22% |
| 2023 Q4 | -7.59 Billion KRW | -22.48% |
| 2023 FY | -35.32 Billion KRW | 1.2% |
| 2023 Q3 | -6.19 Billion KRW | 18.05% |
| 2023 Q2 | -7.56 Billion KRW | 45.86% |
| 2023 Q1 | -13.97 Billion KRW | 5.08% |
| 2022 Q2 | -8.01 Billion KRW | -72.13% |
| 2022 FY | -35.75 Billion KRW | -109.82% |
| 2022 Q3 | -8.36 Billion KRW | -4.43% |
| 2022 Q4 | -14.71 Billion KRW | -75.91% |
| 2022 Q1 | -4.65 Billion KRW | 37.76% |
| 2021 Q1 | -1.21 Billion KRW | -15133.08% |
| 2021 Q3 | -6.59 Billion KRW | -277.52% |
| 2021 Q2 | -1.74 Billion KRW | -43.38% |
| 2021 Q4 | -7.47 Billion KRW | -13.42% |
| 2021 FY | -17.03 Billion KRW | 32.79% |
| 2020 Q3 | -8.18 Million KRW | 0.0% |
| 2020 FY | -25.35 Billion KRW | -87.58% |
| 2020 Q4 | -7.99 Million KRW | 2.25% |
| 2019 FY | -13.51 Billion KRW | 64.03% |
| 2018 FY | -37.57 Billion KRW | -983.45% |
| 2017 FY | -3.46 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 81.317% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -264.345% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 856.298% |
| Bioneer Corporation | -10.58 Billion KRW | -233.661% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -1143.458% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 704.877% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 27.796% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 44.881% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -318.975% |
| Medy-Tox Inc. | 9.75 Billion KRW | 462.116% |
| Peptron, Inc. | -15.92 Billion KRW | -121.863% |
| Amicogen, Inc. | -23.28 Billion KRW | -51.681% |
| Genexine, Inc. | -66.87 Billion KRW | 47.177% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -1434.42% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 52.072% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -947.665% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 146.145% |
| SillaJen, Inc. | -20.36 Billion KRW | -73.422% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 352.936% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | -84.93% |
| Genomictree Inc. | -8.75 Billion KRW | -303.434% |
| D&D Pharmatech | 3.93 Billion KRW | 997.98% |
| EASY BIO,Inc. | 15.54 Billion KRW | 327.26% |
| GI Innovation, Inc. | -55.49 Billion KRW | 36.346% |